Luciano Costa, MD, PhD, Discusses Results That Surprised Him From the MASTER Trial in Multiple Myeloma

Video

Luciano Costa, MD, PhD, spoke about how the results in the final primary analysis of the MASTER trial with daratumumab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma were not what he expected.

At the 2021 American Society of Hematology Annual Meeting, Luciano Costa, MD, PhD, the Aassociate dDirector for Clinical Research at O’Neal Comprehensive Cancer Center, discussed which results of the MASTER trial (NCT03224507) he was most surprised to see when of patients with multiple myeloma who were treated with daratumumab (Darzalex), carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone and what he was most surprised to see come from the data. 

Transcript:

The primary end point of this trial was minimal residual disease [MRD] at 10-5. The surprising part was that [rate] was very high, about 80%, irrespective of risk. That part was the same with patients [who had] 0, 1, or 2 or more high-risk chromosomal abnormalities, and that was a bit surprising. The differences start occurring when you look at [MRD] 10-6; achievement of that was lower in patients with 2 or more high-risk abnormalities. The timing was [also] different and very few of those patients achieved MRD at 10-6 after just induction and most of those did so after transplant. We have progression-free survival [PFS] in 95% of the patients with 0 to 1 high-risk abnormalities. Most of those patients are now off therapy and that part is intriguing. Hopefully, it will inform the design of future trials.

Reference

Costa L, Chhabra S, Medvedova E, et al. Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment cessation. Final primary end point analysis of the Master Trial. Presented at: 63rd American Society of Hematology Annual Conference. December 11-14. Abstract 481. Accessed December 7, 2021. https://bit.ly/3GozUPK

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content